Trial Profile
Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary) ; Metronidazole; Vancomycin
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Results assessing efficacy of Fidaxomicin in patients with Clostridium difficile infections, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 03 Dec 2015 Accrual to date is 116% according to United Kingdom Clinical Research Network.